Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

Mr_Charlie Feb. 3 at 7:25 PM

$PDSB One director left, no news about trial development, share price dropping significaly, big sale today 1.3M at the moment. All signs FDA is kicking Frank ass and saying no! Alert for bankruptcy soon.

1 · Reply

Mr_Charlie Feb. 3 at 7:13 PM

$PDSB I am guessing someone got a tip about the FDA decision and this soon will be 0.20$.

0 · Reply

Mr_Charlie Feb. 3 at 6:29 PM

$PDSB pure garbage, everybody is selling and leaving the Titanic.

0 · Reply

alphabetsop Feb. 3 at 6:00 PM

$PDSB imo many longs finally have moved on and cut their losses and given up on Frank. the remainder have nothing to add that hasn't been said a zillion times. And that IMO is that Frank is absolutely horrible as a leader. Silence may be golden but it feels here that the company is just dying on the vine and they will silently allow it to drift down to prep for a reverse split. Absolute silence from the company and no indication PIII will ever restart recruiting. Should have went with my gut on Frank but didn't. IMO he's the least impressive CEO I've ever seen in this space by a mile. Just saddened his friends on the board of directors don't have the courage to do the right thing IMO.

1 · Reply

EddieH2020 Feb. 3 at 5:34 PM

$PDSB Next time you all should buy SLS instead of this

1 · Reply

xbibackto90s Feb. 3 at 5:19 PM

$PDSB garbage!!! r/s coming

0 · Reply

Knewcomer Feb. 3 at 3:51 PM

$PDSB management just sit on your dicks a while longer. Im long but overly frustrated

0 · Reply

Mr_Charlie Feb. 3 at 3:01 PM

$PDSB pure shite.

0 · Reply

SaySomethingNice Feb. 3 at 2:27 PM

$GXAI $NBY $PDSB $MREO AMAZON WANTS $GXAI AND WILL FUND $$$ OPERATION.. 👍 - imo

0 · Reply

Mr_Charlie Feb. 3 at 1:02 PM

$PDSB 8% up in pre-market, is it another PR coming? Ding Dong!!

0 · Reply

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Jan 22, 2026, 8:45 AM EST - 12 days ago

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

Jan 9, 2026, 8:45 AM EST - 25 days ago

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Dec 9, 2025, 8:00 AM EST - 2 months ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 2 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 10:11 AM EST - 2 months ago

PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:30 AM EST - 2 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 3 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 3 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 3 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 3 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 3 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 4 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:30 AM EDT - 5 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 10:08 AM EDT - 6 months ago

PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:00 AM EDT - 6 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 9, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 9 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 12:57 PM EDT - 9 months ago

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 9 months ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 9 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 10 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 10:35 AM EDT - 11 months ago

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 11 months ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 11 months ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 11:18 AM EST - 1 year ago

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 23, 2024, 10:39 AM EDT - 1 year ago

PDS Biotechnology: Continuing The Holding Pattern

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Mr_Charlie Feb. 3 at 7:25 PM

1 · Reply

Mr_Charlie Feb. 3 at 7:13 PM

$PDSB I am guessing someone got a tip about the FDA decision and this soon will be 0.20$.

0 · Reply

Mr_Charlie Feb. 3 at 6:29 PM

$PDSB pure garbage, everybody is selling and leaving the Titanic.

0 · Reply

alphabetsop Feb. 3 at 6:00 PM

1 · Reply

EddieH2020 Feb. 3 at 5:34 PM

$PDSB Next time you all should buy SLS instead of this

1 · Reply

xbibackto90s Feb. 3 at 5:19 PM

$PDSB garbage!!! r/s coming

0 · Reply

Knewcomer Feb. 3 at 3:51 PM

$PDSB management just sit on your dicks a while longer. Im long but overly frustrated

0 · Reply

Mr_Charlie Feb. 3 at 3:01 PM

$PDSB pure shite.

0 · Reply

SaySomethingNice Feb. 3 at 2:27 PM

$GXAI $NBY $PDSB $MREO AMAZON WANTS $GXAI AND WILL FUND $$$ OPERATION.. 👍 - imo

0 · Reply

Mr_Charlie Feb. 3 at 1:02 PM

$PDSB 8% up in pre-market, is it another PR coming? Ding Dong!!

0 · Reply

Ontherag Feb. 3 at 3:47 AM

$PDSB

1 · Reply

Knewcomer Feb. 2 at 9:59 PM

$PDSB new CEO please

0 · Reply

Eddie5150 Jan. 30 at 7:35 PM

$PDSB they’re going to end up doing a R/S aren’t they?

2 · Reply

Mr_Charlie Jan. 30 at 2:58 PM

$PDSB January over and what did management gave us? Bulshit as always.

0 · Reply

Eddie5150 Jan. 29 at 9:49 PM

$PDSB

0 · Reply

ThatNurseDude Jan. 29 at 7:13 PM

$PDSB Longest we've gone without a trial update is 2 months from 7/25/25 to 9/25/25. We're going 49 days without an update. Hopefully we get an update any sort of update on trial or funding soon....

2 · Reply

Test2025 Jan. 29 at 6:49 PM

$PDSB this shit is perfect for swing traders.Scoop below 1 and sell just above 1, making easily 20% profit a a few times a year

0 · Reply

rockytoday Jan. 29 at 5:25 PM

$PDSB load this. It will be $1 by Monday

0 · Reply

Mr_Charlie Jan. 29 at 5:13 PM

$PDSB I am waiting for the Nasdaq delisting letter.

0 · Reply

Test2025 Jan. 29 at 3:36 PM

$PDSB yeah market sees how desperate company is in milking out every dollar whenever possible. Will punish it hard

0 · Reply

Knewcomer Jan. 29 at 3:32 PM

$PDSB new CEO 🙏

0 · Reply

Mr_Charlie Jan. 29 at 3:10 PM

$PDSB i had some hope. It is all gone now.

0 · Reply

Market Cap	40.79M
Revenue (ttm)	0.00
Net Income (ttm)	-37.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.26

Volume	1,567,400
Avg Vol	710,974
Day's Range	N/A - N/A
Shares Out	48.98M
Stochastic %K	16%
Beta	1.12
Analysts	Strong Sell
Price Target	$7.50